Revance Wins First Daxxify Therapeutic Indication, Plans Limited Initial Rollout
Longer-Lasting Toxin May Have Advantage In Cervical Dystonia
Similar to its post-approval strategy in aesthetics less than a year ago, Revance will initially target a small number of doctors as it Daxxify to market in the US for cervical dystonia with a broader launch in 2024.
